Connor, Clark & Lunn Investment Management Ltd. Mersana Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$4.0 - $7.02 $597,528 - $1.05 Million	-149,382 Reduced 71.67%	59,051 $242,000
Q4 2022 Feb 10, 2023	SELL	$5.65 - $7.86 $283,935 - $394,996	-50,254 Reduced 19.43%	208,433 $1.22 Million
Q3 2022 Nov 10, 2022	BUY	$4.63 - $8.0 $1.2 Million - $2.07 Million	258,687 New	258,687 $1.75 Million
Q1 2021 May 13, 2021	SELL	$15.31 - $26.52 $928,015 - $1.61 Million	-60,615 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$16.84 - $27.59 $1.35 Million - $2.22 Million	-80,409 Reduced 57.02%	60,615 $1.61 Million
Q3 2020 Nov 12, 2020	SELL	$16.2 - $25.7 $317,698 - $504,002	-19,611 Reduced 12.21%	141,024 $2.63 Million
Q2 2020 Aug 13, 2020	BUY	$5.24 - $23.4 $841,727 - $3.76 Million	160,635 New	160,635 $3.76 Million

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

Eco R1 Capital, LLC San Francisco, CA

19.4M
Shares

$39.5 Million
1.59% of portfolio
Nextech Invest Ag

12.1M
Shares

$24.6 Million
3.72% of portfolio
Vr Adviser, LLC New York, NY

11.3M
Shares

$23.1 Million
2.22% of portfolio
Bain Capital Life Sciences Investors, LLC Boston, MA

8.66M
Shares

$17.7 Million
2.94% of portfolio
Black Rock Inc. New York, NY

8.38M
Shares

$17.1 Million
0.0% of portfolio

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account